Shares in Crucell NV surged more than 55 percent Friday on news that Johnson & Johnson, which already holds a 17.9 percent stake in the company, was lining up a €1.75 billion (US$2.3 billion) bid, valued at €24.75 per share, to acquire the Dutch vaccine maker outright. (BioWorld Today)